{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:57:21Z","timestamp":1774479441918,"version":"3.50.1"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Castleman disease (CD) is a relatively rare lymphoproliferative disorder. Lesions predominantly originate on the chest and neck and rarely occur on the abdomen. A 34-year-old female presented to our hospital with an unexplained 10-year history of anemia. A pathological diagnosis of plasma cell-type CD was established. One cycle of chemotherapy (thalidomide, cyclophosphamide, and prednisolone) improved her anemia significantly. Prompt etiological diagnosis and early intervention are essential to address systemic manifestations in patients with CD, and it is crucial to consider CD as a differential diagnosis when intra-abdominal masses are detected.<\/jats:p>","DOI":"10.1515\/biol-2022-0898","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T21:33:14Z","timestamp":1719523994000},"source":"Crossref","is-referenced-by-count":1,"title":["Ten-year anemia as initial manifestation of Castleman disease in the abdominal cavity: A case report"],"prefix":"10.1515","volume":"19","author":[{"given":"Pingping","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College , Xiamen , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College , Xiamen , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigao","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College , Xiamen , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junnan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College , Xiamen , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongquan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College , Xiamen , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"2024062715505024655_j_biol-2022-0898_ref_001","doi-asserted-by":"crossref","unstructured":"Pertusa Mataix R, Loaiza Cabello D, Garcia Morillo JS. Castleman\u2019s disease, pathophysiology, advances in diagnosis and treatment. Med Clin (Barc). 2024;162(6):283\u201390.","DOI":"10.1016\/j.medcle.2023.10.016"},{"key":"2024062715505024655_j_biol-2022-0898_ref_002","doi-asserted-by":"crossref","unstructured":"Kishore A, Rana N, Kumar A, Kashyap V, Jebaying Y. Hyaline vascular variant of castleman disease of the tonsil in an adolescent: a case report. Indian J Otolaryngol Head Neck Surg. 2024;76(1):1062\u20135.","DOI":"10.1007\/s12070-023-04114-4"},{"key":"2024062715505024655_j_biol-2022-0898_ref_003","doi-asserted-by":"crossref","unstructured":"Hoffmann C, Hentrich M, Tiemann M, Rosenwald A, Weber F, Willenbacher W, et al. Recent advances in castleman disease. Oncol Res Treat. 2022;45(11):693\u2013704.","DOI":"10.1159\/000526640"},{"key":"2024062715505024655_j_biol-2022-0898_ref_004","doi-asserted-by":"crossref","unstructured":"Van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020;4(23):6039\u201350.","DOI":"10.1182\/bloodadvances.2020003334"},{"key":"2024062715505024655_j_biol-2022-0898_ref_005","doi-asserted-by":"crossref","unstructured":"Yin L, Lu XY, Xu F, Li AJ, Wu MC. Unicentric Castleman\u2019s disease presenting with growth retardation and iron deficiency anemia. Am J Med Sci. 2012;343(5):426\u20138.","DOI":"10.1097\/MAJ.0b013e318242a212"},{"key":"2024062715505024655_j_biol-2022-0898_ref_006","doi-asserted-by":"crossref","unstructured":"Chandrakasan S, Bakeer N, Mo JQ, Cost C, Quinn CT. Iron-refractory microcytic anemia as the presenting feature of unicentric Castleman disease in children. J Pediatr. 2014;164(4):928\u201330.","DOI":"10.1016\/j.jpeds.2013.11.026"},{"key":"2024062715505024655_j_biol-2022-0898_ref_007","unstructured":"Suh JH, Hong SH, Jeong SC, Park CB, Choi KB, Shin OR, et al. Anemia resolved by thoracoscopic resection of a mediastinal mass: a case report of unicentric Castleman\u2019s disease. J Thorac Dis. 2015;7(7):E189\u201393."},{"key":"2024062715505024655_j_biol-2022-0898_ref_008","doi-asserted-by":"crossref","unstructured":"Kalayoglu Besisik S, Yonal Hindilerden I, Hindilerden F, Dogan IO, Besisik F. A rare cause of unexplained refractory iron deficiency anemia: unicentric plasma-cell type castleman\u2019s disease. Turk J Haematol. 2016;33(3):257\u20138.","DOI":"10.4274\/tjh.2016.0083"},{"key":"2024062715505024655_j_biol-2022-0898_ref_009","doi-asserted-by":"crossref","unstructured":"Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180(2):206\u201316.","DOI":"10.1111\/bjh.15019"},{"key":"2024062715505024655_j_biol-2022-0898_ref_010","doi-asserted-by":"crossref","unstructured":"Patel R, Patel D, Onyechi A, Shaikh S, Patel M, Patel Z. Castleman disease- demographics, associations, and outcomes: an analysis of adult 791 cases. Ann Hematol. 2024;103(4):1255\u201360.","DOI":"10.1007\/s00277-023-05574-y"},{"key":"2024062715505024655_j_biol-2022-0898_ref_011","doi-asserted-by":"crossref","unstructured":"Gonzalez Garcia A, Fernandez-Martin J, Robles Marhuenda A. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology. 2023;62(4):1426\u201335.","DOI":"10.1093\/rheumatology\/keac481"},{"key":"2024062715505024655_j_biol-2022-0898_ref_012","doi-asserted-by":"crossref","unstructured":"Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116(18):3627\u201334.","DOI":"10.1182\/blood-2010-03-271791"},{"key":"2024062715505024655_j_biol-2022-0898_ref_013","doi-asserted-by":"crossref","unstructured":"Van Rhee F. Nearly 70 years later: the continued unraveling of Castleman disease. Haematologica. 2023;108(1):7\u20138.","DOI":"10.3324\/haematol.2022.280902"},{"key":"2024062715505024655_j_biol-2022-0898_ref_014","doi-asserted-by":"crossref","unstructured":"Arenas DJ, Floess K, Kobrin D, Pai RL, Srkalovic MB, Tamakloe MA, et al. Increased mTOR activation in idiopathic multicentric Castleman disease. Blood. 2020;135(19):1673\u201384.","DOI":"10.1182\/blood.2019002792"},{"key":"2024062715505024655_j_biol-2022-0898_ref_015","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, et al. Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019;129(10):4451\u201363.","DOI":"10.1172\/JCI126091"},{"key":"2024062715505024655_j_biol-2022-0898_ref_016","doi-asserted-by":"crossref","unstructured":"Nagy A, Bhaduri A, Shahmarvand N, Shahryari J, Zehnder JL, Warnke RA, et al. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. Blood Adv. 2018;2(5):481\u201391.","DOI":"10.1182\/bloodadvances.2017009654"},{"key":"2024062715505024655_j_biol-2022-0898_ref_017","doi-asserted-by":"crossref","unstructured":"Butzmann A, Kumar J, Sridhar K, Gollapudi S, Ohgami RS. A review of genetic abnormalities in unicentric and multicentric castleman disease. Biology. 2021;10(4):1\u201311.","DOI":"10.3390\/biology10040251"},{"key":"2024062715505024655_j_biol-2022-0898_ref_018","doi-asserted-by":"crossref","unstructured":"Wang S, Wang R, Shang P, Zhu X, Chen X, Zhang G, et al. Whole-exome sequencing reveals the genomic profile and IL6ST variants as a prognostic biomarker of paraneoplastic pemphigus-associated unicentric castleman disease. J Invest Dermatol. 2024;144(3):585\u201392.e1.","DOI":"10.1016\/j.jid.2023.07.031"},{"key":"2024062715505024655_j_biol-2022-0898_ref_019","unstructured":"Chromosome 7: Human Genome Landmarks Poster. Available online: https:\/\/web.ornl.gov\/sci\/techresources\/Human_Genome\/posters\/chromosome\/chromo07.shtml (accessed on 13 July 2020)."},{"key":"2024062715505024655_j_biol-2022-0898_ref_020","doi-asserted-by":"crossref","unstructured":"Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman\u2019s disease: a systematic review of 404 published cases. Ann Surg. 2012;255(4):677\u201384.","DOI":"10.1097\/SLA.0b013e318249dcdc"},{"key":"2024062715505024655_j_biol-2022-0898_ref_021","doi-asserted-by":"crossref","unstructured":"Boutboul D, Fadlallah J, Chawki S, Fieschi C, Malphettes M, Dossier A, et al. Treatment and outcome of Unicentric Castleman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019;186(2):269\u201373.","DOI":"10.1111\/bjh.15921"},{"key":"2024062715505024655_j_biol-2022-0898_ref_022","doi-asserted-by":"crossref","unstructured":"Guo M, Nong L, Wang M, Zhang Y, Wang L, Sun Y, et al. Retrospective cohort evaluation of non-HIV Castleman disease from a single academic center in Beijing, China. Ann Hematol. 2024;103(1):153\u201362.","DOI":"10.1007\/s00277-023-05472-3"},{"key":"2024062715505024655_j_biol-2022-0898_ref_023","doi-asserted-by":"crossref","unstructured":"Rodriguez C, Rivera Rubi L, Menjivar O, Suazo J. The role of radiation therapy in unicentric castleman disease: a case report. Cureus. 2023;15(11):e49687.","DOI":"10.7759\/cureus.49687"},{"key":"2024062715505024655_j_biol-2022-0898_ref_024","doi-asserted-by":"crossref","unstructured":"Remnant L, Kochanova NY, Reid C, Cisneros-Soberanis F, Earnshaw WC. The intrinsically disorderly story of Ki-67. Open Biol. 2021;11(8):210120.","DOI":"10.1098\/rsob.210120"}],"container-title":["Open Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/biol-2022-0898\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/biol-2022-0898\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T21:33:20Z","timestamp":1719524000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/biol-2022-0898\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,27]]},"published-print":{"date-parts":[[2024,6,27]]}},"alternative-id":["10.1515\/biol-2022-0898"],"URL":"https:\/\/doi.org\/10.1515\/biol-2022-0898","relation":{},"ISSN":["2391-5412"],"issn-type":[{"value":"2391-5412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"20220898"}}